Clinical Trial Update: Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating chidamide in combination with toripalimab and anlotinib for recurrent/metastatic nasopharyngeal carcinoma; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Chidamide (chidamide)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING